B2BROKER Introduces PrimeXM XCore Support & Maintenance Services for Brokers
19.2.2025 12:56:00 CET | Business Wire | Press release
B2BROKER has announced the launch of its PrimeXM XCore support and maintenance services, expanding its suite of technology solutions for brokers and financial institutions. This new solution complements the company’s existing support offerings for trading platforms, including cTrader, MT4, and MT5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217935952/en/
B2BROKER's PrimeXM XCore Service provides complete support to manage all technical aspects, including setup and ongoing maintenance, of the PrimeXM XCore server. (Graphic: Business Wire)
PrimeXM XCore in the Trading Industry
PrimeXM’s XCore is a widely used trading and aggregation engine, serving over 250 financial institutions worldwide. It provides ultra-low latency order execution, risk management capabilities, and advanced reporting tools while supporting multi-asset trading across multiple venues.
As a key component in modern brokerage infrastructure, XCore offers brokers improved liquidity access and streamlined execution. However, maintaining and managing the system can be resource-intensive, often requiring the recruitment and training of specialised personnel. Establishing an in-house team to operate XCore typically involves significant time and financial investment.
B2BROKER’s Managed PrimeXM XCore Services
Recognising the operational challenges, B2BROKER has introduced a fully managed PrimeXM XCore service designed to reduce brokers' workloads.
The new service ensures that industry professionals handle all technical aspects of the system, from setup to ongoing maintenance. This allows brokers to focus on business development and client service.
Additionally, B2BROKER introduces a dedicated audit service for clients with an existing PrimeXM server. This service involves a thorough assessment of the setup and detailed recommendations to optimise system performance and ensure a seamless transition under the company’s maintenance.
Arthur Azizov, CEO and Founder of B2BROKER, says:
"We provide comprehensive support to manage all technical aspects of PrimeXM XCore, including setup, ongoing maintenance, and day-to-day operations. No matter the number or type of liquidity providers a broker works with, B2BROKER guarantees seamless trading operations."
Clive Diethelm, CEO and Founder of PrimeXM, comments:
"By collaborating with B2BROKER, we aim to enhance our offerings with flexible support models, ensuring clients can choose solutions that best fit their requirements."
Key Features of the Service
The service package provided by B2BROKER includes:
- Comprehensive System Configuration – Full setup of trading infrastructure, including instruments, asset classes, and user access management.
- Secure Connectivity – Secure and stable integration with liquidity providers and trading venues to ensure seamless execution.
- Customisable Trading Parameters – Adaptation of trading and routing rules to align with each broker’s operational model.
- Continuous Monitoring & Support – 24/7 system oversight to maintain stability and rapid issue resolution.
- Automated Performance Reports – Generation of daily and monthly reports offering insights into system performance and trading efficiency.
Summary
By introducing this service, B2BROKER aims to simplify technical management for brokers relying on PrimeXM XCore. The fully managed approach reduces operational complexities, minimises costs associated with in-house maintenance, and ensures uninterrupted trading operations.
For brokers seeking a reliable and efficient way to manage their PrimeXM XCore infrastructure, B2BROKER’s new service provides a structured solution backed by industry expertise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217935952/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom